Spectral Flow Cytometry in Myeloma: 36 Parameters, No Clonality Gate

A 36-parameter finding with one critical caveat

Pietzsch, Beer, Kimmich, Windsor, Gekeler, Besemer and Stanger describe circulating plasma-cell phenotypes across plasma-cell disease stages in a peer-reviewed original Haematologica study (published online 2 April 2026; October print issue; DOI 10.3324/haematol.2025.300105). Spectral flow cytometry captures intriguing antigen shifts, but the CD56-positive circulating subset was not independently confirmed as clonal. That distinction should govern every clinical interpretation of this work.

Design, instrument and the exact population tested

The authors measured 113 blood PBMC samples: 42 MGUS, 22 smouldering myeloma, 15 newly diagnosed myeloma, 24 treated myeloma and ten healthy controls. Six newly diagnosed patients had matched marrow specimens. A 33-marker, 36-parameter panel on a Cytek Aurora was used after density-gradient separation and cryopreservation, with single-stained cellular/bead unmixing controls and dead-cell exclusion. The exploratory analysis was cross-sectional, not longitudinal tracking of the same patients or a prospective MRD validation study.

Candidate circulating plasma cells were gated as CD45-negative and CD38-high, with CD56 positivity used to define CTPC-like cells. Kappa/lambda light-chain clonality, CD27 and CD81 were not primary identity gates. Samples with 20 or fewer plasma-cell events were excluded from marker-expression analyses. This approach can miss CD56-negative malignant plasma cells and might include rare reactive CD56-positive plasma cells. A fluorescent antigen signature cannot substitute for evidence that an event is clonal.

Phenotypic differences across MGUS, SMM and new myeloma

Within this defined CD56-positive compartment, the authors observed higher CD38 and CD56 and lower CD19, CD14, CD16 and CD45RA from precursor stages towards newly diagnosed disease. CD25 and CD123, as well as CCR6 and CCR7, also differed by stage, while CD20 displayed considerable heterogeneity. Marker statistics used false-discovery-rate adjustment for multiple comparisons. These population-level differences are hypotheses for biological investigation, not validated stage-classification cutoffs for individual blood specimens.

Treated disease and matched marrow are different questions

The 24 treated patients had lower CD38, CD56, CD25 and CD123 in several comparisons against newly diagnosed patients, with other changes in activation and checkpoint markers. Because these groups were not a matched before-and-after cohort, a reversed population pattern does not prove treatment reversed a cell-intrinsic program. Treatments and assay sampling introduce alternative explanations.

Only six matched marrow specimens were available. The paper describes higher CD69, CCR6 and some survival or target-associated markers on marrow plasma cells relative to blood CTPC-like cells. Limited pair counts, unconfirmed clonality and cross-sectional design prevent assigning a universal niche marker signature or extending findings to prediction of extramedullary spread. The study does not establish that an antigen such as BCMA or CD307e can be used here as an independent prognostic threshold.

What a clinical laboratory would need to verify

Define the exact intended measurand: a phenotypically aberrant circulating population, a confirmed clonal tumor-cell count, or analytical MRD. These are not interchangeable. In an intended clinical assay, investigate kappa/lambda restriction and other corroborating findings when technically feasible; challenge CD56-negative tumor phenotypes; assess low-event precision, viability, sample recovery, gating sensitivity and instrument-specific variability. The article reports biological patterns, not EuroFlow NGF equivalence, a new LoD or a validated treatment-response test.

For comparison with other studies, document blood processing and cryopreservation, the cell denominator, background plasma-cell subsets, spectral unmixing setup and analysis software. The 20-event study exclusion should not be copied as a laboratory LoQ without a quantitative verification protocol. Clinical prognostic or monitoring implications require larger independent, longitudinal cohorts.

Daily Learning Pill: phenotype does not prove clonality

Before calling a CD45-negative, CD38-high, CD56-positive cluster a malignant circulating population, ask whether clonality was demonstrated, how CD56-negative tumor cells would be recovered and what the event-count uncertainty is. More colors provide more dimensions, not automatically more certainty about cellular identity.

Evidence scope and further learning

This CFCM Technical Review draws on the published Introduction, Methods, Results, Figure descriptions and Discussion available at the full primary paper; raw cytometry data and the supplementary appendix were not reanalysed. It is original educational interpretation, not independent peer review or clinical validation. Explore CFCM's clinical flow cytometry resources for myeloma immunophenotyping, rare-event QC and analytical verification, and subscribe via the site for future technical appraisals.